Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00903851 · ClinicalTrials.gov registry record · Phase 4
Lidoderm® (Lidocaine Patch 5%) in Diabetic and Idiopathic Neuropathy
A Phase 4 study of Diabetes, sponsored by Endo Pharmaceuticals.
- Completed
- Registry status
- Phase 4
- Development phase
- 76
- Enrollment target
- 4
- Study locations
NCT00903851 is a Phase 4 study of Diabetes that has completed, run by Endo Pharmaceuticals. The registered enrollment target is 76 participants, below the 3,028-participant average among 338 other Diabetes trials with a reported enrollment target (97% lower). The trial reports 4 study locations across 3 states.
The verdict
NCT00903851, a Phase 4 study of Diabetes, has completed, sponsored by Endo Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 76 participants
- Enrollment target
- 4
- Study locations
Study Summary
Patients with Type I or II diabetes and painful distal symmetric sensorimotor polyneuropathy with dynamic allodynia of the lower extremities, patients with Type I or II diabetes and pain distal symmetric sensorimotor polyneuropathy with no dynamic allodynia of the lower extremities, or patients with idiopathic distal predominantly sensory neuropathy participated in a Phase IV clinical trial to assess the efficacy of lidocaine patches in treating painful diabetic neuropathy or idiopathic distal sensory neuropathy.
Conditions Studied
Interventions
- DRUG Lidoderm
Study Locations (4)
Alabama
- - Birmingham
- - Hueytown
Florida
- - Jacksonville
New York
- - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 76 participants |
| Start Date | 2002-04 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00903851
The ClinicalTrials.gov registry entry for NCT00903851 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 76 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,028-participant average among 338 other Diabetes trials with a reported enrollment target (97% lower). The listed sponsor is Endo Pharmaceuticals, which has 23 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Diabetes appearing as the primary indexed condition, and to 1 intervention - of which Lidoderm is the first listed.
NCT00903851 reports 4 study locations spanning 3 distinct geographic areas - top geographies include Alabama, Florida, New York.
Frequently Asked Questions
What is clinical trial NCT00903851 about?
NCT00903851 is a clinical study titled "Lidoderm® (Lidocaine Patch 5%) in Diabetic and Idiopathic Neuropathy". Patients with Type I or II diabetes and painful distal symmetric sensorimotor polyneuropathy with dynamic allodynia of the lower extremities, patients with Type I or II diabetes and pain distal symmetric sensorimotor polyneuropathy with no dynamic allodynia of the lower extremities, or patients with...
What is the current status of trial NCT00903851?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 76 participants. The study started on 2002-04.
What conditions does trial NCT00903851 study?
This clinical trial studies the following conditions: Diabetes.
What interventions are being tested in trial NCT00903851?
The interventions under investigation include: Lidoderm (DRUG).
Who is sponsoring clinical trial NCT00903851?
This trial is sponsored by Endo Pharmaceuticals, which has 23 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00903851 being conducted?
This trial has 4 study locations across Alabama, Florida, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetes
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Efficacy and Mechanisms of Dapagliflozin in Promoting Kidney Function and Cardiovascular Health in Kidney Transplant Recipients
RECRUITING · Phase 4
-
Efficacy of Suvorexant in the Treatment of Insomnia in Midlife Women With Pre-Diabetes
RECRUITING · Phase 4
-
Depression-Diabetes Mechanisms: Urban African Americans
COMPLETED · Phase 4
-
The Effects of Anti-Inflammatory Treatment on Insulin Resistance in Healthy Volunteers
COMPLETED · Phase 4
-
Impact of Dietary Intervention on Weight Change in Subjects With Type 2 Diabetes
COMPLETED · Phase 4
-
Preventing Depression Recurrence in Diabetes
COMPLETED · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.